Partnership17 Mar 2026, 12:10 pm
Lupin and Zydus Partner for Co-marketing Innovative Semaglutide Injection in India
AI Summary
Global pharma major Lupin Limited has entered into a Licensing and Supply Agreement with Zydus Lifesciences Limited to expand access to innovative Semaglutide Injection (15 mg/3 ml) with a patient-friendly reusable pen device in India. This partnership aims to strengthen patient access for advanced diabetes and weight management therapies. Under this agreement, Lupin will have semi-exclusive rights to co-market Zydus’ innovative Semaglutide Injection in India under the brand names Semanext” and Lupin’s Livarise®. Zydus will continue to market the product under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™. The agreement includes upfront licensing fees and milestone payments on achieving pre-defined milestones.
Key Highlights
- Lupin and Zydus have entered into a Licensing and Supply Agreement for co-marketing innovative Semaglutide Injection in India.
- The partnership aims to strengthen patient access for advanced diabetes and weight management therapies.
- Lupin will market the product under the brand names Semanext” and Lupin’s Livarise®.
- Zydus will continue to market the product under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™.
- The agreement includes upfront licensing fees and milestone payments on achieving pre-defined milestones.